Evidence map›Paper›PMID 40664855›Full record

ArticleNature biotechnology2025

Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable.

Sadik H Kassim, Fyodor Urnov, Kiran Musunuru, Ann Lee, Luis Barrera, Pamela Stetkiewicz, Julianne Bruno, Matthew Hewitt, Troy Lister, Harry Malech and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sadik H Kassim *Danaher Corporation, Washington, DC, USA.
Fyodor Urnov *Innovative Genomics Institute, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-7542-4084
Kiran MusunuruPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3298-0368
Ann LeePrime Medicine, Cambridge, MA, USA.
Luis BarreraBeam Therapeutics, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0612-6416
Pamela StetkiewiczArbor Biotechnologies, Cambridge, MA, USA.
Julianne BrunoCRISPR Therapeutics, Boston, MA, USA.
Matthew HewittCharles River Laboratories, Wilmington, MA, USA.
Troy ListerVerve Therapeutics, Boston, MA, USA.
Harry MalechNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5874-5775
Lindsay GaschCapstone Medical Writing & Communications, LLC, Lander, WY, USA.
Matt DiverGalen/Atlantica, Boston, MA, USA.
Nicholas GertlerGalen/Atlantica, Boston, MA, USA.
Felix GrignonInternational Society for Cell & Gene Therapy, Vancouver, British Columbia, Canada.
Audrey LeInternational Society for Cell & Gene Therapy, Vancouver, British Columbia, Canada.
Michael LehmickeAlliance for Regenerative Medicine, Washington, DC, USA.
Edwin M HorwitzAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, GA, USA.
David R LiuThe Broad Institute, Cambridge, MA, USA.
Josephine LembongAlliance for Regenerative Medicine, Washington, DC, USA. jlembong@alliancerm.org.
Vanessa Almendro-NavarroDanaher Corporation, Washington, DC, USA. vanessa.almendro@danaher.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40664855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.